Skip to main content
    S

    Sanofi ADR (SNY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $39.12
    -0.62 (-1.56%)

    Market Cap: $95.29B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(31/39)
    Avg Surprise
    +2.36%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.55
    Range$1.53 - $1.58
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$1.60-2.6%
    60d ago$1.54+0.8%
    30d ago$1.56-0.2%
    7d ago$1.56-0.2%
    Current$1.55
    Revenue Consensus
    $13.2B
    Range$13.1B - $13.3B
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.23
    Range$1.12 - $1.43
    6 analysts
    Revenue Consensus
    $13.5B
    Range$12.1B - $14.1B
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.23---
    Sep 26EST
    		-$1.55---
    Jun 26
    Reported Jul 30
    		$1.21$1.10+10.00%Beat+33.0%
    Mar 26
    Reported Apr 23
    		$1.10$1.03+6.80%Beat+7.8%
    Dec 25
    Reported Jan 29
    		$0.91$0.85+7.06%Beat+33.8%
    Sep 25
    Reported Oct 24
    		$1.69$1.57+7.64%Beat+9.7%
    Jun 25
    Reported Jul 31
    		$0.91$1.00-9.00%Miss-3.2%
    Mar 25
    Reported Apr 24
    		$1.02$0.95+7.37%Beat+7.4%
    Dec 24
    Reported Jan 30
    		$0.68$0.74-8.11%Miss-24.4%
    Sep 24
    Reported Oct 25
    		$1.54$1.38+11.59%Beat+14.1%
    Jun 24
    Reported Jul 25
    		$0.94$0.86+9.30%Beat-2.1%
    Mar 24
    Reported Apr 25
    		$0.95$0.94+1.06%Beat-20.2%
    Dec 23
    Reported Feb 1
    		$0.90$0.91-1.10%Miss-3.2%
    Sep 23
    Reported Oct 27
    		$1.35$1.37-1.46%Miss-6.2%
    Jun 23
    Reported Jul 28
    		$0.96$0.89+7.87%Beat+9.1%
    Mar 23
    Reported Apr 27
    		$1.19$1.10+8.18%Beat+16.7%
    Dec 22
    Reported Feb 3
    		$0.93$0.91+2.20%Beat+17.7%
    Sep 22
    Reported Oct 28
    		$1.44$1.34+7.46%Beat+12.5%
    Jun 22
    Reported Jul 28
    		$0.88$0.87+1.15%Beat+7.3%
    Mar 22
    Reported Apr 28
    		$1.02$0.92+10.87%Beat+5.2%
    Dec 21
    Reported Feb 4
    		$0.79$0.72+9.72%Beat+8.2%
    Sep 21
    Reported Oct 28
    		$1.28$1.17+9.40%Beat+18.5%
    Jun 21
    Reported Jul 29
    		$0.82$0.75+9.33%Beat+9.3%
    Mar 21
    Reported Apr 28
    		$0.97$1.23-21.14%Miss+10.2%
    Dec 20
    Reported Feb 5
    		$0.73$1.05-30.48%Miss-1.4%
    Sep 20
    Reported Oct 29
    		$1.08$1.03+4.85%Beat+0.9%
    Jun 20
    Reported Jul 29
    		$0.75$0.64+17.19%Beat+2.7%
    Mar 20
    Reported Apr 24
    		$0.88$0.82+7.32%Beat+11.4%
    Dec 19
    Reported Feb 6
    		$0.74$0.69+7.25%Beat+17.5%
    Sep 19
    Reported Oct 31
    		$1.07$1.04+2.88%Beat+2.9%
    Jun 19
    Reported Jul 29
    		$0.73$0.72+1.39%Beat+0.0%
    Mar 19
    Reported Apr 26
    		$0.79$0.77+2.60%Beat+2.6%
    Dec 18
    Reported Feb 7
    		$0.63$0.67-5.97%Miss-3.1%
    Sep 18
    Reported Oct 31
    		$1.04$1.00+4.00%Beat+4.0%
    Jun 18
    Reported Jul 31
    		$0.73$0.72+1.39%Beat-8.8%
    Mar 18
    Reported Apr 27
    		$0.77$0.69+11.59%Beat+0.0%
    Dec 17
    Reported Feb 7
    		$0.65$1.04-37.50%Miss-3.0%
    Sep 17
    Reported Nov 2
    		$1.00$0.96+4.17%Beat-
    Jun 17
    Reported Jul 31
    		$0.80$0.76+5.26%Beat-
    Mar 17
    Reported Apr 28
    		$0.77$0.70+10.00%Beat-
    Dec 16
    Reported Feb 8
    		$0.67$0.67+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield6.19%
    Forward Annual Dividend$2.42
    Payout Ratio34.98%
    FrequencyAnnual
    Pay MonthsJun

    Growth

    3Y CAGR+7.91%
    5Y CAGR+4.60%
    SNY dividend history and ex-dividend datesRun SNY in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio7.97EV/EBITDA6.47x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin8.09%Operating Margin21.00%
    ROE5.71%ROIC7.68%
    Financial Health
    Debt/Equity0.31xInterest Coverage11.29x
    Current Ratio0.99xQuick Ratio0.23x
    Trading Statistics
    Beta0.28Avg Volume3.13M
    52-Week High$49.9152-Week Low$39.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$40.02
    SMA 20$40.95
    SMA 50$42.82
    SMA 200$43.68
    EMA 10$40.08
    EMA 20$40.85
    EMA 50$42.13
    EMA 200$43.70

    MACD

    Line: -0.98Signal: -0.92Hist: -0.06

    ADX

    ADX: 25.6+DI: 15.3-DI: 34.2

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down100.0
    PSAR$41.25

    Bollinger Bands

    Upper Band$43.35
    Lower Band$38.56
    %B Position1168%(Upper)
    Band Width0.12

    RSI (14-Day)

    Oversold
    28.6

    Momentum Oscillators

    Stoch %K15.9
    Stoch %D22.9
    Williams %R-98.2
    ROC (10d)-4.0%
    Momentum-1.62
    CCI (20d)-106.3
    MFI (14d)29.4

    Volatility Measures

    ATR (14d)$0.74(1.9%)
    StdDev (20d)1.20
    Hist Vol17.5%(Low)

    Volume Flow

    VWAP$39.44
    OBV-9.4M
    AD Line-6.4B
    CMF (20d)-0.063

    Volume Metrics

    Avg Vol (20d)3.2M
    Vol Ratio1.3x
    VWMA (20d)$40.86

    Pivot Points

    R3$40.77
    R2$40.54
    R1$40.14
    Pivot Point$39.91
    S1$39.51
    S2$39.28
    S3$38.88

    Advanced Oscillators

    TSI-35.70
    Ultimate Osc42.2
    KST-79.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12.30B$11.24B$12.21B$13.17B$10.73B$10.61B$7.63B$14.16B$11.38B$9.73B$12.20B$12.70B
    Cost of Revenue$3.02B$3.14B$3.63B$3.41B$2.99B$2.89B$2.27B$4.08B$3.41B$2.97B$4.05B$3.84B
    Gross Profit$9.28B$8.11B$8.57B$9.76B$7.74B$7.72B$5.36B$10.07B$7.97B$6.76B$8.15B$8.86B
    Operating Expenses$6.90B$5.84B$9.61B$6.13B$6.27B$5.48B$4.79B$6.44B$6.38B$5.52B$7.81B$5.65B
    R&D$2.23B$1.75B$2.29B$1.83B$1.91B$1.81B$2.12B$1.85B$1.70B$1.67B$1.87B$1.66B
    SG&A$2.46B$2.33B$3.44B$2.29B$2.19B$2.22B$1.24B$2.68B$2.65B$2.60B$2.93B$2.58B
    Operating Income$2.38B$2.27B$-1,038,000,000$3.62B$1.47B$2.23B$573.00M$3.63B$1.59B$1.24B$342.00M$3.21B
    Interest Income$77.00M$60.00M$33.00M$114.00M$76.00M$86.00M$1.00M$133.00M$92.00M$151.00M$117.00M$143.00M
    Interest Expense$287.00M$178.00M$100.59M$227.00M$201.37M$213.00M$302.11M$265.00M$304.16M$247.00M$293.88M$318.00M
    Income Before Tax$828.00M$2.01B$-1,155,000,000$3.51B$1.47B$2.20B$451.00M$3.58B$1.42B$1.09B$-249,000,000$3.10B
    Income Tax Expense$451.00M$420.00M$-348,000,000$680.00M$230.00M$481.00M$4.00M$737.00M$299.00M$104.00M$309.00M$563.00M
    Net Income$343.00M$1.61B$-801,000,000$2.80B$3.94B$1.87B$499.00M$2.81B$1.11B$1.13B$-555,000,000$2.52B
    EBITDA$4.04B$2.72B$3.82B$4.20B$3.27B$2.77B$2.58B$4.17B$2.78B$1.87B$2.82B$3.92B
    EBIT$1.12B$2.18B$1.85B$3.74B$1.51B$2.37B$354.00M$3.77B$1.53B$1.38B$-150,000,000$3.35B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    5 High-Yield Dividend Picks for Q4 2026

    5 High-Yield Dividend Picks for Q4 2026 EPD 6.29%, fee-based pipeline, distribution covered 1.75x LTM, A-rated, 27 straight annual increases, predictable contract cash flows SNY 5.88%, AA-rated, payout ~50% of business earnings, Dupixent sales grew 38% last quarter...

    Connor Graham
    •
    10/2/26
    •
    615
    dividends, high-yield, income-investing, stock-picks
    Also mentions:
    LKQVICISNYHRL

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789...

    Glenn Ford
    •
    2/27/26
    •
    177
    Biotech, BioPharma
    Also mentions:
    SNYAMGNTMDXGILD

    Paid 4.7% to Wait: Why Sanofi Anchors My Defensive Sleeve

    SNY offers 32% margin of safety to $63 BFV with 94 quality score, among highest in my tracked universe Beta of 0.27 makes SNY genuine defensive ballast vs AI/growth holdings (NVDA 2.09, GOOGL 1.16, META 1.51) 4.7% yield with 18% debt and 19.1x interest coverage...

    Glenn Ford
    •
    1/24/26
    •
    198
    Barbell Strategy, defensive stocks, value investing
    Also mentions:
    PFEBTINVDAGOOGL

    Government Contracts

    Gov Obligations (TTM)
    $51.16M
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    -32.5%
    Active Awards
    147
    New Awards (TTM)
    129
    Avg Remaining Term
    10.7 mo

    Top agency: Department of Health and Human Services at 79.7% of trailing twelve month obligations across 6 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75A50125F61012Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$24.87MSep 5, 2025
    SPE2DP26F2910Department of DefenseDefense Logistics Agency$2.99MFeb 20, 2026
    SPE2DP26F2847Department of DefenseDefense Logistics Agency$2.92MFeb 20, 2026
    75H71126F80051Department of Health and Human ServicesIndian Health Service$2.00MMar 15, 2026
    SPE2DP26F2912Department of DefenseDefense Logistics Agency$1.99MFeb 20, 2026
    SPE2DP26F2909Department of DefenseDefense Logistics Agency$824486Feb 20, 2026
    75A50126F61013Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$697439May 8, 2026
    SPE2DP26F1179Department of DefenseDefense Logistics Agency$486741Dec 12, 2025
    15F06726F0000243Department of JusticeFederal Bureau of Investigation$200000Jan 1, 2026
    19AQMM25F1492Department of StateDepartment of State$176565Sep 9, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Sanofi cycles deeper into sports marketing niche as Tour de France partner

    Sanofi has announced a major sponsorship with the 2027 Tour de France, becoming the first company to sponsor the white jersey for best young rider in both the men's and women's races. This partnership aims to leverage...

    Fierce Pharma•10/16/26•Bullish

    Sanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care

    Sanofi has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a Letter of Intent for Dupixent across four new indications: pediatric atopic dermatitis, prurigo nodularis...

    BioSpace•10/15/26•Bullish

    Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

    Recursion Pharmaceuticals Inc. (RXRX) saw its shares surge after Sanofi initiated the development of drug molecules from their collaboration, leading to a $10 million milestone payment for Recursion...

    Yahoo Finance•10/15/26•Somewhat-Bullish

    Recursion wins $200M investment, Sanofi milestone (RXRX:NASDAQ)

    Recursion (RXRX) announced a $200 million equity offering, which initially led to a more than 4% drop in its premarket trading. This investment news overshadowed a positive development where Sanofi (SNY) selected its...

    Seeking Alpha•10/15/26•Somewhat-Bullish

    Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

    Recursion Pharmaceuticals announced that Sanofi has optioned a potential first-in-class immunology development candidate from their collaboration...

    Yahoo Finance•10/15/26•Somewhat-Bullish

    SNY Valuation and Fair Value

    P/E
    8.0x
    Forward P/E
    8.6x
    EV/EBITDA
    6.5x
    PEG
    28.6x
    P/B
    1.2x
    See GNG's fair value

    SNY Profitability: Margins, ROIC and FCF

    Gross margin
    73.0%
    Operating margin
    21.0%
    Net margin
    8.1%
    ROIC
    7.7%
    ROE
    5.7%
    FCF margin
    17.7%

    SNY Competitors

    CompanyTicker
    HCA Healthcare, Inc.HCA
    GlaxoSmithKline PLC ADRGSK
    Stryker CorporationSYK
    Elevance Health IncELV
    CVS Health CorpCVS
    Moderna IncMRNA
    McKesson CorporationMCK
    Regeneron Pharmaceuticals IncREGN

    Sector: Healthcare

    SNY Analyst Ratings

    Consensus
    Hold
    Analysts
    10
    Strong Buy
    0
    Buy
    5
    Hold
    5
    Sell
    0
    Strong Sell
    0

    SNY Bull Case vs Bear Case

    Bull case

    • SNY converts 17.7% of revenue into free cash flow.
    • SNY beat EPS estimates in 75.0% of its last 8 reported quarters.
    • SNY grew quarterly revenue 14.6% year over year.

    SNY Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    4.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $1.55
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    SNY Dividend

    Forward yield
    6.2%
    Payout ratio
    35.0%
    3Y DPS growth
    7.9%
    5Y DPS growth
    4.6%
    Pay months
    Jun
    SNY dividend history

    Frequently Asked Questions About SNY

    What is SNY's current dividend yield?

    Sanofi ADR (SNY) has a forward dividend yield of 6.19%.

    Does SNY pay dividends?

    Yes, Sanofi ADR pays dividends with a forward dividend yield of 6.19%.

    What is SNY's P/E ratio?

    Sanofi ADR has a price-to-earnings (P/E) ratio of 7.97.

    What is SNY's market cap?

    Sanofi ADR (SNY) has a market capitalization of $95.29B with a current stock price of $39.12.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In